Rs2910164 Polymorphism Confers a Decreased Risk for Pulmonary Hypertension by Compromising the Processing of microRNA-146a

Cellular Physiology and Biochemistry

Volumn 36, Issue 5, 2015, Pages 1951-1960

  Liu, Haitao ^a   Chen, Mai ^a   Wu, Feng ^a   Li, Fei ^a   Yin, Tao ^a   Cheng, Hexiang ^a   Li, Weijie ^a   Liu, Bing ^a   Wang, Qiong ^a   Tao, Ling ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

COX2; MIR 146a; PGI2; Pulmonary hypertension; rs2910164

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA 146A; PROSTACYCLIN; RNA PRECURSOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MICRORNA; MIRN146 MICRORNA, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REAL TIME POLYMERASE CHAIN REACTION; RNA PROCESSING; SMOOTH MUSCLE FIBER; UPREGULATION; WESTERN BLOTTING; AGED; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, GENETIC; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 84937939778     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430163     Document Type: Article

References (38)

1. Schannwell CM, Steiner S, Strauer BE: Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007;58:591-602.
2. Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, Riascos DF, Chung SW, Schissel SL, Ingber DE, Mitsialis SA, Kourembanas S, Perrella MA: Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 2008;117:2114-2122.
3. Ismail S, Sturrock A, Wu P, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T, Hoidal J: NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: The role of autocrine production of transforming growth factor-1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 2009;296:L489-L499.
4. Ruan CH, Dixon RA, Willerson JT, Ruan KH: Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J 2010;37:391-399.
5. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
6. Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: The implications for cancer research. Nat Rev Cancer 2010;10:389-402.
7. Yang Q, Jie Z, Ye S, Li Z, Han Z, Wu J, Yang C, Jiang Y: Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility. Oncogene 2014;33:193-202.
8. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A: Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008;105:7269-7274.
9. Chen L, Zhang R, Li P, Liu Y, Qin K, Fa ZQ, Liu YJ, Ke YQ, Jiang XD: P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neurosci Lett 2013;534:327-332.
10. Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, Qiu Y, Xie Q, Ge J: Notch1 promotes glioma cell migration and invasion by stimulating beta-catenin and NF-kappaB signaling via AKT activation. Cancer Sci 2012;103:181-190.
11. Mei J, Bachoo R, Zhang CL: MicroRNA-146a inhibits glioma development by targeting Notch1. Mol Cell Biol 2011;31:3584-3592.
12. Treanor LM, Volanakis EJ, Zhou S, Lu T, Sherr CJ, Sorrentino BP: Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood 2011;117:5453-5462.
13. Permuth-Wey J, Thompson RC, Burton Nabors L, Olson JJ, Browning JE, Madden MH, Ann Chen Y, Egan KM: A functional polymorphism in the pre-miR-146a gene is associated with risk and prognosis in adult glioma. J Neurooncol 2011;105:639-6461.
14. Mei J, Bachoo R, Zhang CL: MicroRNA-146a inhibits glioma development by targeting Notch1. Mol Cell Biol 2011;31:3584-3592.
15. Liu XR, Liu Q, Chen GY, Hu Y, Sham JS and Lin MJ: Down-regulation of TRPM8 in pulmonary arteries of pulmonary hypertensive rats. Cell Physiol Biochem 2013;31:892-904.
16. Chen L, Li YS, Cui J, Ning JN, Wang GS, Qian GS, Lu KZ, Yi B: MiR-206 controls the phenotypic modulation of pulmonary arterial smooth muscle cells induced by serum from rats with hepatopulmonary syndrome by regulating the target gene, annexin A2. Cell Physiol Biochem 2014;34:1768-1779.
17. Long W, Zhao C, Ji C, Ding H, Cui Y, Guo X, Shen R, Liu J: Characterization of serum microRNAs profile of PCOS and identification of novel non-invasive biomarkers. Cell Physiol Biochem 2014;33:1304-1315.
18. Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR, Fu JF: Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem 2014;34:1983-1997.
19. Ezzie ME1, Crawford M, Cho JH, Orellana R, Zhang S, Gelinas R, Batte K, Yu L, Nuovo G, Galas D, Diaz P, Wang K, Nana-Sinkam SP: Gene expression networks in COPD: microRNA and mRNA regulation. Thorax 2012;67:122-131.
20. Savarimuthu Francis SM, Davidson MR, Tan ME,Wright CM, Clarke BE, Duhig EE, Bowman RV, Hayward NK, Fong KM, Yang IA: MicroRNA-34c is associated with emphysema severity and modulates SERPINE1 expression. BMC Genomics 2014;15:88.
21. Bartels CL and Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009;55:623-631.
22. Liang H, Gu Y, Li T, Zhang Y, Huangfu L, Hu M, Zhao D, Chen Y, Liu S, Dong Y, Li X, Lu Y, Yang B, Shan H: Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis. Cell Death Dis 2014;5:e1238.
23. Gao LB, Bai P, Pan XM, Jia J, Li LJ, Liang WB, Tang M, Zhang LS, Wei YG, Zhang L: The association between two polymorphisms in pre-miRNAs and breast cancer risk: A meta-analysis. Breast Cancer Res Treat 2011;125:571-574.
24. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, Zeng Y, Miao R, Jin G, Ma H, Chen Y, Shen H: Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118:2600-2608.
25. Jazdzewski K1, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A: Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2008;105:7269-7274.
26. Moncada S: Prostacyclin and arterial wall biology. Arteriosclerosis 1982;2:193-207.
27. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors: subtypes and signalling. Annu Rev Pharmacol Toxicol 2001;41:661-690.
28. Gardner AM1, Vaillancourt RR, Johnson GL: Activation of mitogen-activated protein kinase/ extracellular signal-regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J Biol Chem 1993;268:17896-17901.
29. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 2002;4:45-61.
30. Wang AX, Xu B, Tong N, Chen SQ, Yang Y, Zhang XW, Jiang H, Liu N, Liu J, Hu XN, Sha GZ, Chen M: Meta-analysis confirms that a common G/C variant in the pre-miR-146a gene contributes to cancer susceptibility and that ethnicity, gender and smoking status are risk factors. Genet Mol Res 2012;11:3051-3062.
31. Hamajima N, Takezaki T, Matsuo K, Saito T, Inoue M, Hirai T, Kato T, Ozeki J, Tajima K: Genotype Frequencies of Cyclooxygenease 2 (COX2) Rare Polymorphisms for Japanese with and without Colorectal Cancer. Asian Pac J Cancer Prev 2001;2:57-62.
32. Lin HJ, Lakkides KM, Keku TO, Reddy ST, Louie AD, Kau IH, Zhou H, Gim JS, Ma HL, Matthies CF, Dai A, Huang HF, Materi AM, Lin JH, Frankl HD, Lee ER,Hardy SI, Herschman HR, Henderson BE, Kolonel LN, Le Marchand L, Garavito RM, Sandler RS, Haile RW, Smith WL: Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002;11:1305-1315.
33. Goodman JE, Bowman ED, Chanock SJ, Alberg AJ, Harris CC: Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis 2004;25:2467-2472.
34. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC: Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. Br J Cancer 2004; 90:1760-1764,.
35. Siezen CL, Bueno-de-Mesquita HB, Peeters PH, Kram NR, van Doeselaar M,van Kranen HJ: Polymorphisms in the genes involved in the arachidonic acid-pathway, fish consumption and the risk of colorectal cancer. Int J Cancer 2006;119:297-303.
36. Siezen CL, Tijhuis MJ, Kram NR, van Soest EM, de Jong DJ, Fodde R, van Kranen HJ, Kampman E: Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics 2006;16:43-50.
37. Poole EM, Bigler J, Whitton J, Sibert JG, Kulmacz RJ, Potter JD, Ulrich CM: Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps. Carcinogenesis 2007;28:1259-1263.
38. Tan W, Wu J, Zhang X, Guo Y, Liu J, Sun T, Zhang B, Zhao D, Yang M, Yu D, Lin D: Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer. Carcinogenesis 2007;28:1197-1201.